BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 11267978)

  • 1. Suppression of proline-directed protein kinase F(A) systemically inhibits the growth of human acute leukemia cells.
    Hsu CP; Yang CC; Yang SD
    Int J Cancer; 2001 Mar; 91(5):650-53. PubMed ID: 11267978
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Suppression of proline-directed protein kinase F(A) expression inhibits the growth of human chronic myeloid leukaemia cells.
    Hsu CP; Hsueh SF; Yang CC; Yang SD
    Br J Cancer; 2000 Apr; 82(8):1480-4. PubMed ID: 10780530
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antisense suppression of proline-directed protein kinase FA enhances chemosensitivity in human prostate cancer cells.
    Yang CC; Hsu CP; Yang SD
    Clin Cancer Res; 2000 Mar; 6(3):1024-30. PubMed ID: 10741730
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Suppression of proline-directed protein kinase F(A) expression potentiates erythroid differentiation of human myeloid leukemia cells.
    Hsu CP; Yang CC; Yang SD
    Cancer; 2000 Sep; 89(5):1004-11. PubMed ID: 10964330
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Suppression of proline-directed protein kinase F(A) inhibits the malignant growth of human pancreatic ductal adenocarcinoma.
    Fu HH; Yang SD
    Anticancer Res; 2004; 24(3a):1489-94. PubMed ID: 15274314
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Suppression of proline-directed protein kinase F(A) potentiates apoptotic induction and greatly enhances chemosensitivity in human acute lymphoblastic leukemia cells.
    Hsu CP; Yang CC; Hsueh SF; Peng CC; Fu HH; Yang SD
    Cancer; 2001 Oct; 92(7):1753-8. PubMed ID: 11745246
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of proline-directed protein kinase FA with tumorigenesis, invasion, and poor prognosis of human colon carcinoma.
    Chung YC; Chang KJ; Yang CC; Lai MT; Hsu CP; Hsueh SF; Peng CC; Fu HH; Chang YF; Yang SD
    Cancer; 2002 Nov; 95(9):1840-7. PubMed ID: 12404276
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of overexpressed proline-directed protein kinase F(A) with chemoresistance, invasion, and recurrence in patients with bladder carcinoma.
    Hsueh SF; Lai MT; Yang CC; Chung YC; Hsu CP; Peng CC; Fu HH; Cheng YM; Chang KJ; Yang SD
    Cancer; 2002 Aug; 95(4):775-83. PubMed ID: 12209721
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proline-directed protein kinase FA as a new signal transducing target for lethal cancer treatment.
    Yang SD
    Drug News Perspect; 2005 Sep; 18(7):432-6. PubMed ID: 16362082
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Co-purification of p34cdc2/p58cyclin A proline-directed protein kinase and the retinoblastoma tumor susceptibility gene product: interaction of an oncogenic serine/threonine protein kinase with a tumor-suppressor protein.
    Williams RT; Carbonaro-Hall DA; Hall FL
    Oncogene; 1992 Mar; 7(3):423-32. PubMed ID: 1532245
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proline-directed protein kinase FA is a powerful and independent prognostic predictor for progression and patient survival of hepatocellular carcinoma.
    Hsu YC; Fu HH; Jeng YM; Lee PH; Yang SD
    J Clin Oncol; 2006 Aug; 24(23):3780-8. PubMed ID: 16754939
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proline-directed protein kinase FA as a potential target for diagnosis and therapy of human cancers.
    Yang SD
    Curr Cancer Drug Targets; 2004 Nov; 4(7):591-6. PubMed ID: 15578916
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bioflavonoids commonly and potently induce tyrosine dephosphorylation/inactivation of oncogenic proline-directed protein kinase FA in human prostate carcinoma cells.
    Lee SC; Kuan CY; Yang CC; Yang SD
    Anticancer Res; 1998; 18(2A):1117-21. PubMed ID: 9615775
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acute inductive effects on oncogenic proline-directed protein kinase FA/GSK-3 alpha in NIH 3T3 cells by ethanol and cadmium.
    Sheu JC; Hsu CP; Yang CC; Yang SD
    Proc Natl Sci Counc Repub China B; 1998 Apr; 22(2):68-75. PubMed ID: 9615469
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phosphorylation of RII subunit and attenuation of cAMP-dependent protein kinase activity by proline-directed protein kinase.
    Braun RK; Vulliet PR; Carbonaro-Hall DA; Hall FL
    Arch Biochem Biophys; 1991 Aug; 289(1):187-91. PubMed ID: 1654846
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nutrient mixture inhibits in vitro and in vivo growth of human acute promyelocytic leukemia HL-60 cells.
    Roomi MW; Roomi NW; Bhanap B; Rath M; Niedzwiecki A
    Exp Oncol; 2011 Dec; 33(4):212-5. PubMed ID: 22217709
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oligonucleotide sequence-specific inhibition of gene expression, tumor growth inhibition, and modulation of cAMP signaling by an RNA-DNA hybrid antisense targeted to protein kinase A RIalpha subunit.
    Nesterova M; Cho-Chung YS
    Antisense Nucleic Acid Drug Dev; 2000 Dec; 10(6):423-33. PubMed ID: 11198926
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overexpression of protein kinase FA/GSK-3 alpha (a proline-directed protein kinase) correlates with human hepatoma dedifferentiation/progression.
    Yang SD; Yu JS; Yang CC; Lee SC; Lee TT; Ni MH; Kuan CY; Chen HC
    J Cell Biochem; 1996 May; 61(2):238-45. PubMed ID: 9173087
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Antisense human telomerase reverse transcriptase inhibits leukemia cell proliferation in vitro].
    Sun LB; Li CR; Wen JM; Wang GB; Zhang M; Yang J; Li RX
    Di Yi Jun Yi Da Xue Xue Bao; 2004 May; 24(5):521-4. PubMed ID: 15151822
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differentiation of HL-60 leukemia by type I regulatory subunit antisense oligodeoxynucleotide of cAMP-dependent protein kinase.
    Tortora G; Yokozaki H; Pepe S; Clair T; Cho-Chung YS
    Proc Natl Acad Sci U S A; 1991 Mar; 88(5):2011-5. PubMed ID: 2000408
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.